Literature DB >> 29956745

Silencing Ubc9 expression suppresses osteosarcoma tumorigenesis and enhances chemosensitivity to HSV-TK/GCV by regulating connexin 43 SUMOylation.

Dianying Zhang1, Kai Yu2, Zhong Yang2, Yanxia Li3, Xiaofang Ma3, Xiyun Bian3, Fengting Liu4, Lili Li4, Xiaozhi Liu3, Wenhan Wu5.   

Abstract

The ability of herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) systems to kill tumor cells is partially dependent on the integrity of gap junction intercellular communication (GJIC) of targeted tumor cells. Recent studies have suggested that connexin 43 (Cx43), which serves a role in gap junction-mediated intercellular communication, is regulated by small ubiquitin-like modifiers (SUMOs). However, the roles of these post-translational modifications remain to be elucidated. The present study demonstrated overexpression of SUMO‑conjugating enzyme Ubc9 (Ubc9) protein in osteosarcoma. Silencing Ubc9 by siRNA inhibited osteosarcoma cell proliferation and migration, and significantly increased the sensitivity of cells to HSV-TK/GCV systems both in vitro and in vivo. Further experimentation demonstrated that silencing Ubc9 induced decoupling of SUMO1 from Cx43, generating increased free Cx43 levels, which is important for reconstructing GJIC and recovering cellular functions. In conclusion, the present study revealed a novel method for the effective restoration of GJIC in osteosarcoma cells, which may increase their sensitivity to conventional chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29956745     DOI: 10.3892/ijo.2018.4448

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Oncogene UBE2I enhances cellular invasion, migration and proliferation abilities via autophagy-related pathway resulting in poor prognosis in hepatocellular carcinoma.

Authors:  Xiang-Kun Wang; Xi-Wen Liao; Xin Zhou; Chuang-Ye Han; Zi-Jun Chen; Cheng-Kun Yang; Jian-Lu Huang; Jian-Yao Wang; Jun-Qi Liu; Hua-Sheng Huang; Shu-Tian Mo; Xin-Ping Ye; Guang-Zhi Zhu; Tao Peng
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 2.  SUMOylation and NEDDylation in Primary and Metastatic Cancers to Bone.

Authors:  Marta Gomarasca; Giovanni Lombardi; Paola Maroni
Journal:  Front Cell Dev Biol       Date:  2022-04-06

3.  Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma.

Authors:  Xiaolan Su; Yang Wan; Linshen Xie; Xiufang Lin; Hongwen Zhao; Xiao Ju; Aiping Fang
Journal:  Med Sci Monit       Date:  2019-09-06

Review 4.  SUMOylation in Skeletal Development, Homeostasis, and Disease.

Authors:  Huadie Liu; Sonya E L Craig; Vladimir Molchanov; Joseph S Floramo; Yaguang Zhao; Tao Yang
Journal:  Cells       Date:  2022-08-31       Impact factor: 7.666

Review 5.  An overview of resistance to chemotherapy in osteosarcoma and future perspectives.

Authors:  Dorian Yarih Garcia-Ortega; Sara Aileen Cabrera-Nieto; Haydee Sarai Caro-Sánchez; Marlid Cruz-Ramos
Journal:  Cancer Drug Resist       Date:  2022-06-23

6.  UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma.

Authors:  Hao Yang; Shan Gao; Jing Chen; Weiyang Lou
Journal:  Cancer Cell Int       Date:  2020-06-12       Impact factor: 5.722

Review 7.  Antagonistic Functions of Connexin 43 during the Development of Primary or Secondary Bone Tumors.

Authors:  Julie Talbot; Maryne Dupuy; Sarah Morice; Françoise Rédini; Franck Verrecchia
Journal:  Biomolecules       Date:  2020-08-26

8.  Expression and Prognosis Analysis of SUMOylation Regulators in Oral Squamous Cell Carcinoma Based on High-Throughput Sequencing.

Authors:  Yutong Meng; Xiaozhi Li
Journal:  Front Genet       Date:  2021-06-29       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.